The effect of immunosuppression on manifestations of sepsis in an animal model of cecal ligation and puncture.

[1]  M. Fink.  Animal models of sepsis , 2013, Virulence.

[2]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[3]  R. Hotchkiss,et al.  Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure , 2012 .

[4]  S. Kusne,et al.  Infection control issues after solid organ transplantation , 2012 .

[5]  Y. Novitsky,et al.  Evaluation of serum cytokine release in response to hand-assisted, laparoscopic, and open surgery in a porcine model. , 2011, American journal of surgery.

[6]  D. Ganea,et al.  Cecal ligation puncture procedure. , 2011, Journal of visualized experiments : JoVE.

[7]  V. Rada,et al.  Interference of Bifidobacterium choerinum or Escherichia coli Nissle 1917 with Salmonella Typhimurium in gnotobiotic piglets correlates with cytokine patterns in blood and intestine , 2011, Clinical and experimental immunology.

[8]  J. Vincent,et al.  Sepsis biomarkers: a review , 2010, Critical care.

[9]  B. Holzmann,et al.  COMBINED IMMUNOSUPPRESSIVE AND ANTIBIOTIC THERAPY IMPROVES BACTERIAL CLEARANCE AND SURVIVAL OF POLYMICROBIAL SEPTIC PERITONITIS , 2010, Shock.

[10]  J. Fishman.  Introduction: Infection in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Anand Kumar,et al.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. , 2009, Chest.

[12]  S. Zanotti-Cavazzoni,et al.  Animal models of sepsis. , 2009, Critical care clinics.

[13]  M. Georgieff,et al.  Hemodynamic, metabolic, and organ function effects of pure oxygen ventilation during established fecal peritonitis-induced septic shock , 2009, Critical care medicine.

[14]  M. Georgieff,et al.  Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial , 2009, Critical care.

[15]  N. Azarpira,et al.  Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. , 2009, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[16]  J. Granger,et al.  Stratification is the key: Inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis* , 2009, Critical care medicine.

[17]  S. Chadban,et al.  Immunosuppression in renal transplantation: some aspects for the modern era. , 2008, Transplantation reviews.

[18]  K. Reinhart,et al.  The Role of Procalcitonin in Febrile Neutropenic Patients: Review of the Literature , 2008, Infection.

[19]  B. C. Hellerud,et al.  New Biomarkers in an Acute Model of Live Escherichia coli‐induced Sepsis in Pigs , 2008, Scandinavian journal of immunology.

[20]  K. Becker,et al.  Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations , 2008, Critical care medicine.

[21]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[22]  E. Bouza,et al.  Fever of unknown origin in solid organ transplant recipients. , 2007, Infectious disease clinics of North America.

[23]  John A Kellum,et al.  Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. , 2007, Archives of internal medicine.

[24]  D. Rittirsch,et al.  The disconnect between animal models of sepsis and human sepsis , 2007, Journal of leukocyte biology.

[25]  Marc Moss,et al.  The role of infection and comorbidity: Factors that influence disparities in sepsis , 2006, Critical care medicine.

[26]  S. Chu,et al.  Sparing immunosuppression in heart transplant recipients with severe sepsis. , 2006, Transplantation proceedings.

[27]  Javed Siddiqui,et al.  Circulating Cytokine/Inhibitor Profiles Reshape the Understanding of the SIRS/CARS Continuum in Sepsis and Predict Mortality1 , 2006, The Journal of Immunology.

[28]  F. Budak,et al.  Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[29]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[30]  Marc Moss,et al.  The effect of age on the development and outcome of adult sepsis* , 2006, Critical care medicine.

[31]  S. Opal,et al.  THE USE OF IMMUNOCOMPROMISED ANIMALS AS MODELS FOR HUMAN SEPTIC SHOCK , 2005, Shock.

[32]  Kirby I Bland,et al.  CECAL LIGATION AND PUNCTURE , 2005, Shock.

[33]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[34]  J. Siddiqui,et al.  Role of Interleukin-6 in Mortality from and Physiologic Response to Sepsis , 2005, Infection and Immunity.

[35]  K. Wakitani,et al.  Comparative Study of Glucocorticoids, Cyclosporine A, and JTE-607 [(-)-Ethyl-N-{3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl}-l-phenylalaninate Dihydrochloride] in a Mouse Septic Shock Model , 2004, Journal of Pharmacology and Experimental Therapeutics.

[36]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[37]  S. Trzeciak,et al.  Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. , 2004, The American journal of emergency medicine.

[38]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[39]  R. Speich,et al.  Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  A. González-Quintela,et al.  Cecal Ligation and Puncture as a Model of Sepsis in the Rat: Influence of the Puncture Size on Mortality, Bacteremia, Endotoxemia and Tumor Necrosis Factor Alpha Levels , 2001, European Surgical Research.

[41]  T. Crabtree,et al.  Characteristics of infectious complications associated with mortality after solid organ transplantation , 2000, Clinical transplantation.

[42]  S. Opal,et al.  Immunocompromised Animals in Sepsis Research , 1998 .

[43]  C. Natanson,et al.  The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure , 1994, The Journal of experimental medicine.

[44]  C. Wanidworanun,et al.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. , 1993, Journal of immunology.

[45]  P. Sweny.  Infection in solid organ transplant recipients , 1989 .

[46]  W. Sibbald,et al.  Renal and cardiovascular response to nonhypotensive sepsis in a large animal model with peritonitis. , 1985, Surgery.

[47]  M. Mathru.  Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock , 2010 .

[48]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[49]  J. Buras,et al.  A Practical Approach to Animal Models of Sepsis , 2008 .